tetrahydro-3aH-cyclopenta[d][1,3]dioxole

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氧戊环
• 英文名称: tetrahydro-3aH-cyclopenta[d][1,3]dioxole
• 英文别名: 4,5,6,6a-tetrahydro-3aH-cyclopenta[d][1,3]dioxole
• 化学式: C₆H₁₀O₂
• 分子量: 114.144
• InChiKey: XWGANFXPAPDBQD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  8
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  18.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  1,2-环氧环戊烷 、 二氧化碳 在 四丁基碘化铵 作用下， 以 neat (no solvent) 为溶剂， 110.0 ℃ 、101.33 kPa 条件下， 反应 12.0h， 以90%的产率得到tetrahydro-3aH-cyclopenta[d][1,3]dioxole
  参考文献：
  名称：

  最先进的邻苯二酚卟啉COF催化剂，可通过环状碳酸酯和恶唑烷酮化学固定二氧化碳†

  摘要：

  合成了一种高度多孔的邻苯二酚卟啉晶体，并将其用作有机催化剂，用于二氧化碳的化学固定，以在无溶剂和无过渡金属的条件下合成增值化学品，例如环状碳酸酯和恶唑烷酮。COF催化剂的高表面积和功能性协同作用以活化原料。2,3-DhaTph在二氧化碳的大气压下对环状碳酸酯表现出出色的活性。另外，该催化体系本质上是可回收的，并且比以前报道的有机催化剂提供更高的营业额。

  DOI：

  10.1039/c6cy00362a

文献信息

• [EN] THIENOPYRIMIDINE DERIVATIVE AND USE THEREOF IN MEDICINE<br/>[FR] DÉRIVÉ DE THIÉNOPYRIMIDINE ET SON UTILISATION EN MÉDECINE
  申请人：SUNSHINE LAKE PHARMA CO LTD

  公开号：WO2018133858A1

  公开（公告）日：2018-07-26

  The present invention relates to a thienopyrimidine derivative and use thereof in medicine, and also to a pharmaceutical composition containing the compound. The compound or pharmaceutical composition is used for inhibiting acetyl-CoA carboxylase (ACC). The present invention also relates to a method of preparing such compound and pharmaceutical composition, as well as their use in the treatment or prevention of diseases regulated by acetyl-CoA carboxylase in mammals, especially in humans.

  本发明涉及一种噻吡嘧啶衍生物及其在医学上的用途，以及含有该化合物的药物组合物。该化合物或药物组合物用于抑制乙酰辅酶A羧化酶（ACC）。本发明还涉及一种制备该化合物和药物组合物的方法，以及它们在哺乳动物，特别是人类中治疗或预防由乙酰辅酶A羧化酶调节的疾病的用途。
• [EN] THIENOPYRIMIDINE DERIVATIVES AS ACC INHIBITORS AND USES THEREOF<br/>[FR] DÉRIVÉS DE THIÉNOPYRIMIDINE SUBSTITUÉS UTILISÉS EN TANT QU'INHIBITEURS D'ACC ET LEURS UTILISATIONS
  申请人：GILEAD SCIENCES INC

  公开号：WO2021030142A1

  公开（公告）日：2021-02-18

  The present disclosure relates generally to compounds that bind to Acetyl-CoA Carboxylase (ACC) and act as inhibitors of ACC. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of ACC, including liver diseases such as non-alcoholic fatty liver disase (NAFLD) and non-alcoholic steatohepatitis (NASH).

  本公开涉及一般与结合乙酰辅酶A羧化酶（ACC）并作为ACC的抑制剂的化合物有关。此外，本公开还涉及利用这些化合物制备药物以治疗通过结合ACC引起的疾病和/或状况，包括非酒精性脂肪肝病（NAFLD）和非酒精性脂肪性肝炎（NASH）等肝病。
• METAL CATALYSTS FOR SELECTIVE FORMATION OF CYCLIC CARBONATES, PROCESS FOR PREPARING CYCLIC CARBONATE USING THE SAME AND USE OF CYCLIC CARBONATE
  申请人：KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY

  公开号：US20170081302A1

  公开（公告）日：2017-03-23

  Provided are a novel metal catalyst for preparing cyclic carbonate, and a method for preparing cyclic carbonate using the same, and more particularly, a method for selectively preparing cyclic carbonate in a high yield and at a higher conversion rate as compared to the existing catalysts, using the metal complex including a ligand represented by Chemical Formula 1 below and a trivalent metal in Group 8 or Group 13 as a catalyst and using various structures of epoxide compounds and carbon dioxide as raw materials. In addition, provided are the prepared cyclic carbonate, and an electrolyte including the same: in Chemical Formula 1, R 1 is hydrogen, (C1-C20)alkyl or halogen; R 2 is hydrogen, (C1-C20)alkyl, (C1-C20)alkoxy, halogen or nitro.

  提供了一种用于制备环状碳酸酯的新型金属催化剂，以及使用该催化剂制备环状碳酸酯的方法，更具体地说，使用包括化学式1所示的配体和第8族或第13族的三价金属作为催化剂，并利用环氧化合物和二氧化碳等原料，以高产率和更高转化率选择性制备环状碳酸酯的方法，相较于现有催化剂。此外，提供了制备的环状碳酸酯，以及包括该碳酸酯的电解质：在化学式1中，R1为氢、(C1-C20)烷基或卤素；R2为氢、(C1-C20)烷基、(C1-C20)烷氧基、卤素或硝基。
• SUBSTITUTED CYCLOALKENE DERIVATIVE
  申请人：Kimura Tomio

  公开号：US20090233952A1

  公开（公告）日：2009-09-17

  [Object] To provide a substituted cycloalkene derivative having an action to suppress intracellular signal transduction or cell activation induced by endotoxin and to suppress cell responses due to the intracellular signal transduction and cell activation such as an excess generation of inflammatory mediators such as TNF-α, pharmacologically acceptable salts therefor, a medicament containing them as an active ingredient, a preparation method therefor, and a medicament containing the aforementioned substituted cycloalkene derivative as an active ingredient which is superior in prophylaxis and/or treatment of diseases such as sepsis (septic shock, disseminated intravascular coagulation, multiple organ failure and the like), that are associated with intracellular signal transduction or cell activation induced by endotoxin and to cell responses to the intracellular signal transduction and cell activation. [Solution] A compound represented by the general formula (I): wherein X and Y represent a group in which X and Y together with a carbon atom to which they are bound form ring A (the ring is 3- to 7-membered heterocyclyl ring or 3- to 7-membered cycloalkyl ring), each represents a hydrogen atom, or X and Y together represent a substituent of ring B. l and m, independently from each other, represent an integer of 0 to 3, and l+m is 1 to 3. R 1 is an aliphatic hydrocarbon group and the like which may be substituted with a group selected from Substituent group β and Substituent group γ. n represents an integer of 0 to 3. R 2 is a C 1 -C 6 alkyl group and the like which may be substituted with a group selected from a hydrogen atom and Substituent group β. R 3 is a phenyl group, 5- to 6-membered heteroaryl group and the like which may be substituted with a group selected from Substituent group ε. R 5 is a C 1 -C 6 alkyl group and the like which may be substituted with a group selected from a hydrogen atom and Substituent group β. Provided that in the case where R 3 is a phenyl group which may be substituted with a group selected from Substituent group ε, X and Y represent a group in which X and Y together with a carbon atom to which they are bound form ring A, or X and Y together represent a substituent of ring B.

  [目的] 提供一种替代环烯烃衍生物，具有抑制内毒素诱导的细胞内信号传导或细胞活化并抑制细胞对细胞内信号传导和细胞活化的反应，例如过量生成TNF-α等炎症介质，其药理学上可接受的盐，包含其作为活性成分的药物，其制备方法以及含有上述替代环烯烃衍生物作为活性成分的药物，其在预防和/或治疗与内毒素诱导的细胞内信号传导或细胞活化以及对细胞内信号传导和细胞活化的反应有关的疾病，例如败血症（败血性休克，弥漫性血管内凝血，多器官衰竭等）方面具有优越性。 [解决方案] 一种由通式（I）表示的化合物：其中，X和Y表示与它们结合的碳原子形成环A（环为3-至7成员的杂环或3-至7成员的环烷基环）的基团，每个表示氢原子，或X和Y一起表示环B的取代基。l和m，独立地，表示0至3的整数，且l+m为1至3。R1是脂肪烃基等，可以被从取代基组β和取代基组γ中选择的基团取代。n表示0至3的整数。R2是C1-C6烷基等，可以被从氢原子和取代基组β中选择的基团取代。R3是苯基，5-至6成员的杂环基等，可以被从取代基组ε中选择的基团取代。R5是C1-C6烷基等，可以被从氢原子和取代基组β中选择的基团取代。但在R3是苯基且可以被从取代基组ε中选择的基团取代的情况下，X和Y表示与它们结合的碳原子形成环A的基团，或X和Y一起表示环B的取代基。
• Transthyretin (TTR) iRNA compositions and methods of use thereof for treating or preventing TTR-associated diseases
  申请人：Alnylam Pharmaceuticals, Inc.

  公开号：US10683501B2

  公开（公告）日：2020-06-16

  The present invention provides iRNA agents, e.g., double stranded iRNA agents, that target the transthyretin (TTR) gene and methods of using such iRNA agents for treating or preventing TTR-associated diseases.

  本发明提供了靶向转甲状腺素（TTR）基因的 iRNA 制剂，如双链 iRNA 制剂，以及使用这种 iRNA 制剂治疗或预防 TTR 相关疾病的方法。